Evidence map›Paper›PMID 36313289›Full record

ArticleFrontiers in pharmacology2022

Exploring the druggability of the binding site of aurovertin, an exogenous allosteric inhibitor of F

Luis Fernando Cofas-Vargas, Paola Mendoza-Espinosa, Luis Pablo Avila-Barrientos, Diego Prada-Gracia, Héctor Riveros-Rosas, Enrique García-Hernández

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. FInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Luis Fernando Cofas-VargasUniversidad Nacional Autónoma de México, Instituto de Química, Ciudad Universitaria, Mexico City, Mexico.
Paola Mendoza-EspinosaUniversidad Nacional Autónoma de México, Instituto de Química, Ciudad Universitaria, Mexico City, Mexico.
Luis Pablo Avila-BarrientosUniversidad Nacional Autónoma de México, Instituto de Química, Ciudad Universitaria, Mexico City, Mexico.
Diego Prada-GraciaUnidad de Investigación en Biología Computacional y Diseño de Fármacos, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Héctor Riveros-RosasDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Cd. Universitaria, Mexico City, Mexico.
Enrique García-HernándezUniversidad Nacional Autónoma de México, Instituto de Química, Ciudad Universitaria, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to playing a central role in the mitochondria as the main producer of ATP, F

Indexed as

bacterial pathogensbinding free energyconformational dynamicsFOF1-ATP synthase inhibitionhot spot binding residuessolvent sites

Identifiers

PMID36313289
PMCPMC9615146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.